In a prospective cross-sectional study, the BladderChek test, combined with a cystoscopic examination, detected 99% of all recurrent cancers, according to H. Barton Grossman, M.D., of the M.D. Anderson Cancer Center.
Also, the test alone detected eight of nine cancers that were not found during initial cystoscopy, Dr. Grossman and colleagues reported in the Jan. 18 issue of the Journal of the American Medical Association.
By contrast, the standard urine cytology test, combined with cystoscopy, detected 94.2% of cancers - a rate of detection that was not significantly greater than that of cystoscopy alone, the researchers found.
The BladderChek test, manufactured by Matritech of Newton, Mass., detects elevated amounts of nuclear mitotic apparatus protein, or NMP22, which is released into urine during cell death.
Unlike standard urine cytology, the test for NMP22 does not require whole cancer cells and can be done in a physician's office while the patient waits. It is also cheaper than cytology, the researchers noted.
Age - 55
T1 G3 - Tumor free 2 yrs 3 months
Dx January 2006
thanks for the information, Rosemary. My cytology report has always come back negative, even when CIS was found. I am happy to see there are other tests to check. You always share such helpful information - thanks:)